Journal
IMMUNOTHERAPY
Volume 10, Issue 3, Pages 171-175Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0126
Keywords
checkpoint inhibitors; exocrine glands; immune-related colitis; immunotherapy; pancreatic enzymes; pembrolizumab
Categories
Funding
- Simon Kerr Fellowship
Ask authors/readers for more resources
We report a case of isolated immune-related pancreatic exocrine insufficiency in a patient treated with pembrolizumab for metastatic melanoma. This patient presented with explosive diarrhea and was treated with high dose corticosteroids for possible immune-related colitis. However, biopsies from colon and duodenum did not show any histological evidence of colitis/enteritis. Serum amylase and lipase were not elevated. There was no evidence of pancreatitis or pancreatic metastases on imaging. Significantly lower fecal elastase test on two occasions confirmed the diagnosis of pancreatic exocrine insufficiency. He was treated with pancreatic enzyme supplementation with complete resolution of diarrhea. This case reinforces the importance of awareness and anticipation of unusual immune-related adverse events related to checkpoint inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available